A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
With a nod to Dickens given that it’s the holidays, I’ve been thinking about biosimilars past, present and future lately. In that holiday spirit, even though the parallels aren’t perfect to the classic holiday story, let’s look at the biosimilar
(Washington, D.C.) — As independent drugstore lobbyists descend on Harrisburg for their lobby day, the Pharmaceutical Care Management Association (PCMA) released the following statement: “Pharmacy benefit managers (PBMs) advocate on behalf of Pennsylvania’s consumers and health plan sponsors by negotiating with drug manufacturers and
Unlocking an Affordable Future Unlocking an Affordable Future NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics Stop The
Voices from around the nation, including small business owners and concerned citizens, have sounded the alarm on proposals targeting pharmacy benefit companies in Congress, specifically how policies would lead to increased health care costs for consumers, patients, and families, and
Pharmacy Benefit Managers reduce prescription drug costs for patients and use innovative technology to help patients get their prescriptions and lead healthier lives.
Between January 2022 and January 2023, the total number of independent pharmacies nationwide increased by 99, a 0.4% increase. Looking at the new five-year trend, the number of independent pharmacies has increased by 0.5%. Overall, the 2023 pharmacy counts have
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake and put an end to brand manufacturers’ tactics to extend exclusivity on brand-name biologics. As more
(Washington, D.C.) — As Congress begins to examine high prescription drug prices, the Pharmaceutical Care Management Association (PCMA) sent letters to several congressional committees highlighting the value pharmacy benefit managers (PBMs) provide to patients and payers as well as outlining
PBMs leverage competition between drugs to create savings for patients.
©2024 PCMA. All Rights Reserved.
